Daniel J. Espinoza

Dan Espinoza is a partner in the firm’s Business Law Department and leads the firm’s Special Purpose Acquisition Companies (“SPAC”) practice. Mr. Espinoza advises clients in all aspects of the SPAC lifecycle, including forming and structuring sponsor entities, representing SPACs and SPAC sponsors in initial public offerings (“IPOs”); and representing operating companies, their investors and SPACs in business combinations.

Mr. Espinoza is also a member of the firm’s M&A/Corporate Governance practice and Technology group, where he has extensive experience in mergers and acquisitions. Mr. Espinoza’s practice encompasses all aspects of mergers and acquisitions, including representing domestic and foreign entities, private equity sponsors, and investment banks in private and public company transactions. 

While focusing on the technology and life sciences sectors, Mr. Espinoza’s practice spans a number of industries, including biotechnology, cryptocurrency, internet of things, digital media, consumer products, telecommunications, and e-commerce.

Mr. Espinoza has recently advised on the following transactions:

• Akili Interactive Labs, Inc. in its business combination with Social Capital Suvretta Holdings Corp. I.
• G Squared Ascend I in its business combination with Transfix, Inc.
• Forge Global in its business combination with Motive Capital Corp.
• Milk Makeup LLC in its business combination with Obagi Global Holdings Limited and Waldencast Acquisition Corp.
• Social Finance, Inc., in its business combination with Social Capital Hedosophia Holdings Corp. V.
• Open Lending LLC in its business combination with Nebula Acquisition Corp.
• PTK Acquisition Corp. in its business combination with Valens Semiconductor.
• Cerevel Therapeutics Inc. in its business combination with Arya Sciences Acquisition Corp. II.
• Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. in its business combination with POINT Biopharma.
• Cano Health in its business combination with JAWS Acquisition Corp.
• Gemini Therapeutics in its business combination with FS Development Corp.
• Clarus Therapeutics Holdings, Inc., in its business combination with Blue Water Acquisition Corp.
• Nerdy Inc. in its business combination with TPG Pace Tech Opportunities.
• Immatics in its business combination with Arya Sciences Acquisition Corp.
• Powered Brands in its SPAC IPO.
• Chain Bridge I in its SPAC IPO.
• Big Sky Growth Partners Inc. in its SPAC IPO.
• Vy Global Growth in its SPAC IPO.
• Qell Acquisition Corp. in its SPAC IPO.
• Ribbit LEAP, Ltd. in its SPAC IPO.
• Research Alliance Corp. II in its SPAC IPO.
• one in its SPAC IPO.
• Prime Impact Acquisition I in its SPAC IPO.
• Global Growth in its $500 million SPAC IPO.
• Qell Acquisition Corp. in its $330 million SPAC IPO.
• Ribbit LEAP, Ltd. in its $350 million SPAC IPO.
• Open Lending LLC in its business combination with Nebula Acquisition Corp.
• Cerevel Therapeutics Inc. in its business combination with Arya Sciences Acquisition Corp. II.
• Immatics in its business combination with Arya Sciences Acquisition Corp.
• Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. in its $135.7 million SPAC IPO.
• one in its $200 million SPAC IPO.
• Prime Impact Acquisition I in its $300 million SPAC IPO.

Mr. Espinoza is a member of the California Bar Association.

Prior to joining Goodwin, Mr. Espinoza was an associate in the Palo Alto office of Cooley LLP.